Study Group: Physicians who Treat Malignant Melanoma (US)
Council Members in this Study Group: 179
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
Donald FlemingDivision Head of Hematology and Oncology
DAVIS HEALTH SYSTEM INC
Donald Fleming, MD, is the Head of Hematology-Oncology at the Medical Center of Vincennes. Previously, Dr. Fleming was a Tenured Professor in the Division of Hematology-Oncology at University of Louisville. He has published over 25 manuscripts in peer-reviewed...
Taral PatelOncologist
MID-OHIO ONCOLOGY & HEMOTOLOGY INCTaral Patel, MD, is an Oncologist in private practice with Mid Ohio Oncology-Hematology, Inc. He treats patients with both cancer and blood disorders. Dr. Patel has been a principal investigator for multiple clinical trials in colon cancer, lung cancer,...
Sunil DhawanClinical Assistant Professor of Dermatology
STANFORD UNIVERSITYSunil Dhawan, MD, is a Clinical Assistant Professor of Dermatology at Stanford University. He has expertise in clinical dermatology including acne, rosacea, psoriasis, eczema, skin cancer, actinic keratosis, lasers and cosmetic dermatology, and managed...
- Brian Lester
Dermatologist
Brian W Lester, MDBrian Lester, MD, is a Dermatologist in private practice in Massachusetts. His interests include clinical dermatology, cosmetic dermatology, dermatopathology, and dermatologic pharmaceuticals. He has experience with clinical trials involving a variety...
Michele PauporteDermatologist
JUVA SKIN LASER CENTER INCMichele Pauporte, MD, is a dermatologist at Juva Skin and Laser Center, in New York City. Dr. Pauporte's areas of expertise include cosmetic procedures and the treatment of skin cancers, including Mohs micrographic surgery and reconstructive surgery....
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
November 19, 2009
Leo Pharma completes merger pact with Peplin | www.pharmabiz.com
The recent merger of Peplin with Leo pharma is of some significance and will benefit both companies. It would have been difficult for Peplin to fully develop and market their flagship product alone.
-
November 14, 2009
US FDA accepts ChemGenex's Omapro NDA filing to treat CML, grants priority review status | www.pharmabiz.com
Patients with CML have a good prognosis when treated with TKI's An exception is the ones that develope a particular mutation known as T315IOnly SCT seems to be effective in this group of patients and maybe too morbid of therapy for many patients
-
Synta Drug for Metastatic Melanoma Not Dead Yet (?)
November 3, 2009
Synta Pharmaceuticals Announces Updated Elesclomol SYMMETRYSM Data Presented at Melanoma XIII | www.businesswire.com
Updated data presented at an annual Melanoma conference suggests the drug Elesclomol may benefit a subset of patients treated on a Phase III trial. This Synta Pharmaceuticals-sponsored trial in metastatic melanoma patients was stopped for safety (survival) concerns in February 2009, but the updated analysis suggests that a commonly available biomarker may identify patients who appear to benefit from Elesclomol treatment.This news is important because it may allow Synta to continue to pursue approval for Elesclomol in either melanoma patients or in other cancers. They will report an updated survival analysis twelve months after the protocol was stopped, after February 2010. Further info from Synta is expected soon.
-
Delcath Phase III trial for metastatic melanoma completes enrollment
November 3, 2009
Delcath Systems, Inc. Completes Phase III Study Enrollment | www.reuters.com
The Delcath Systems Percutaneous Hepatic Perfusion (PHP) trial to treat patients with metastatic melanoma has completed enrollment and now must track patients, record data, and analyze results.This trial was apparently enrolled on schedule and the company is targeting 2010 for FDA regulatory submission.
-
Particle Beam Technology - Costly and a limited utility
October 26, 2009
Particle Beam Radiation Therapy published by AHRQ | effectivehealthcare.ahrq.gov
Over the last several years, there has been an increased interest in the US in particle beam therapy as the costs have come down and large manufacturers have become more efficient in installing these centers. In addition, private companies have made a business model of building proton centers - mostly by treating prostate cancer.Protons are incredibly useful in specific diseases - ie ocular melanoma, pediatric cancers, but are too costly without proven benefit for our health care system.
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Academic Institution*
- Non-Academic Community Hospital or Clinic
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Physician - Director
- Owner
- Director
- President
- Physician - Division Head
- Partner
- Physician - Department Chair
Related Study Groups
| Study Group Name | No. Members |
|---|---|
| Oncologists (US) | 2241 |
| Skin Cancer Oncologists (US) | 108 |
| Dermatologists (US) | 616 |
| Hematologists and Oncologists in Private Practice (US) | 462 |
| Oncologists in Private Practice in the U.S. | 451 |
| Physicians who Treat Acne (US) | 302 |
| Hair Restoration Dermatologists (US) | 285 |
| Cosmetic Dermatologists (US) | 280 |